| Year |
Citation |
Score |
| 2018 |
Takebe N, Coyne GHO, Kummar S, Do KT, Bruns A, Juwara L, Quinn MF, Harris L, Piekarz R, Prindiville SA, Sharon E, Streicher H, Mugundu G, Ji JJ, Wilsker D, et al. Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775. Journal of Clinical Oncology. 36: 2587-2587. DOI: 10.1200/Jco.2018.36.15_Suppl.2587 |
0.34 |
|
| 2018 |
O'Sullivan Coyne GH, Do KT, Kummar S, Takebe N, Quinn MF, Piha-Paul SA, Bruns A, Juwara L, Sharon E, Piekarz R, Streicher H, Rubinstein L, Wilsker D, Kinders RJ, Parchment RE, et al. Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 2549-2549. DOI: 10.1200/Jco.2018.36.15_Suppl.2549 |
0.376 |
|
| 2017 |
O'Sullivan Coyne GH, Kummar S, Meehan RS, Juwara L, Piekarz R, Sharon E, Streicher H, Conley BA, Takebe N, Harris L, Doyle A, Quinn MF, Rubinstein L, Wilsker D, Kinders RJ, et al. Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors. Journal of Clinical Oncology. 35: TPS2609-TPS2609. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2609 |
0.396 |
|
| 2017 |
Meehan RS, Chen AP, Coyne GO, Kummar S, Ji J, Vilimas R, Juwara L, Kinders RJ, Ferry-Galow K, Wilsker D, Zhang Y, Dull AB, Navas T, Wang L, Parchment RE, et al. Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations Cancer Research. 77: 4678-4678. DOI: 10.1158/1538-7445.Am2017-4678 |
0.335 |
|
| 2016 |
Wilsker D, Marrero AM, Dull A, Pfister TD, Lawrence SM, Carter J, Gottholm-Ahalt M, Hollingshead M, Doroshow J, Parchment RE, Kinders RJ. Abstract B24: Ataxia-telangiectasia and Rad3-related (ATR) phosphorylation as a pharmacodynamic biomarker of ATR activation in solid tumor tissue models Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Cellcycle16-B24 |
0.332 |
|
| 2012 |
Wilsker D, Chung JH, Bunz F. Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells. Cell Cycle (Georgetown, Tex.). 11: 1564-72. PMID 22433954 DOI: 10.4161/Cc.19944 |
0.381 |
|
| 2012 |
Wilsker D, Chung JH, Pradilla I, Petermann E, Helleday T, Bunz F. Targeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survival. Molecular Cancer Therapeutics. 11: 98-107. PMID 22084169 DOI: 10.1158/1535-7163.Mct-11-0675 |
0.393 |
|
| 2011 |
Wilsker DF, Chung JH, Bunz F. Abstract LB-188: Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cells Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-188 |
0.428 |
|
| 2009 |
Wilsker D, Bunz F. Chk1 phosphorylation during mitosis: a new role for a master regulator. Cell Cycle (Georgetown, Tex.). 8: 1161-3. PMID 19282670 DOI: 10.4161/Cc.8.8.8148 |
0.422 |
|
| 2008 |
Wilsker D, Petermann E, Helleday T, Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proceedings of the National Academy of Sciences of the United States of America. 105: 20752-7. PMID 19091954 DOI: 10.1073/Pnas.0806917106 |
0.469 |
|
| 2007 |
Wilsker D, Bunz F. Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival. Molecular Cancer Therapeutics. 6: 1406-13. PMID 17431119 DOI: 10.1158/1535-7163.Mct-06-0679 |
0.38 |
|
| 2007 |
Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene. 26: 2535-2542. PMID 17043640 DOI: 10.1038/Sj.Onc.1210049 |
0.354 |
|
| 2005 |
Wilsker D, Probst L, Wain HM, Maltais L, Tucker PW, Moran E. Nomenclature of the ARID family of DNA-binding proteins. Genomics. 86: 242-51. PMID 15922553 DOI: 10.1016/J.Ygeno.2005.03.013 |
0.571 |
|
| 2005 |
Patsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Research. 33: 66-80. PMID 15640446 DOI: 10.1093/Nar/Gki145 |
0.728 |
|
| 2004 |
Wang X, Nagl NG, Wilsker D, Van Scoy M, Pacchione S, Yaciuk P, Dallas PB, Moran E. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. The Biochemical Journal. 383: 319-25. PMID 15170388 DOI: 10.1042/Bj20040524 |
0.676 |
|
| 2004 |
Wilsker D, Patsialou A, Zumbrun SD, Kim S, Chen Y, Dallas PB, Moran E. The DNA-binding properties of the ARID-containing subunits of yeast and mammalian SWI/SNF complexes. Nucleic Acids Research. 32: 1345-53. PMID 14982958 DOI: 10.1093/Nar/Gkh277 |
0.74 |
|
| 2004 |
Zheng P, Patel B, McMenamin M, Paprocki AM, Schramm RD, Nagl NG, Wilsker D, Wang X, Moran E, Latham KE. Expression of genes encoding chromatin regulatory factors in developing rhesus monkey oocytes and preimplantation stage embryos: possible roles in genome activation. Biology of Reproduction. 70: 1419-27. PMID 14724134 DOI: 10.1095/Biolreprod.103.023796 |
0.643 |
|
| 2002 |
Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 13: 95-106. PMID 11959810 |
0.733 |
|
| 2000 |
Dallas PB, Pacchione S, Wilsker D, Bowrin V, Kobayashi R, Moran E. The Human SWI-SNF Complex Protein p270 Is an ARID Family Member with Non-Sequence-Specific DNA Binding Activity Molecular and Cellular Biology. 20: 3137-3146. PMID 10757798 DOI: 10.1128/Mcb.20.9.3137-3146.2000 |
0.634 |
|
| Show low-probability matches. |